Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response
- 26 June 2014
- journal article
- Published by American Society of Hematology in Blood
- Vol. 123 (26) , 4045-4053
Abstract
Ex vivo gene therapy strategies avoid systemic delivery of viruses thereby mitigating the risk of vector-associated immunogenicity. Previously, we delivered autologous factor VIII (FVIII)-expressing blood outgrowth endothelial cells (BOECs) to hemophilia A mice and showed that these cells remained sequestered within the implanted matrix and provided therapeutic levels of FVIII. Prior to translating this strategy into the canine (c) model of hemophilia A, we increased cFVIII transgene expression by at least 100-fold with the use of the elongation factor 1 alpha (EF1α) promoter and a strong endothelial enhancer element. BOECs isolated from hemophilia A dogs transduced with this lentiviral vector express levels of cFVIII ranging between 1.0 and 1.5 U/mL per 106 cells over 24 hours. Autologous BOECs have been implanted into the omentum of 2 normal and 3 hemophilia A dogs. These implanted cells formed new vessels in the omentum. All 3 hemophilia A dogs treated with FVIII-expressing autologous BOECs developed anti-FVIII immunoglobulin G2 antibodies, but in only 2 of the dogs were these antibodies inhibitory. FVIII antigen levels >40% in the absence of FVIII coagulant function were detected in the circulation for up to a year after a single gene therapy treatment, indicating prolonged cellular viability and synthesis of FVIII. Key Points Implanting autologous FVIII-expressing BOECs results in sustained FVIII antigen in hemophilia dogs. Anti-FVIII immunoglobulin G2 antibodies develop.Keywords
This publication has 44 references indexed in Scilit:
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia BNew England Journal of Medicine, 2011
- Bioengineering of coagulation factor VIII for efficient expression through elimination of a dispensable disulfide loopJournal of Thrombosis and Haemostasis, 2011
- A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia AMolecular Therapy, 2011
- Codon optimization of human factor VIII cDNAs leads to high-level expressionBlood, 2011
- Trp2313-His2315 of Factor VIII C2 Domain Is Involved in Membrane BindingJournal of Biological Chemistry, 2010
- A role for thrombin in the initiation of the immune response to therapeutic factor VIIIBlood, 2009
- Antioxidants reduce endoplasmic reticulum stress and improve protein secretionProceedings of the National Academy of Sciences, 2008
- In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearanceBlood, 2006
- LMAN1 and MCFD2 Form a Cargo Receptor Complex and Interact withCoagulation Factor VIII in the Early SecretoryPathwayJournal of Biological Chemistry, 2005
- Dangerous liaisons: the role of “danger” signals in the immune response to gene therapyBlood, 2002